Comparison of Betamethasone and Methotrexate efficacy in the Treatment of Alopecia Areata
Phase 3
- Conditions
- Alopecia Areata.Alopecia areata
- Registration Number
- IRCT20181226042136N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
The scalp involvement rate more than 50%
The disease is resistant to systemic and topical combination therapy
The patient is satisfied with the study
Exclusion Criteria
Pregnancy or Breastfeeding
Hb less than 9mg/dl
Leukocyte less than 4000
Platelet less than 100000
Potassium is less than 3.5
Liver enzymes 2 times more than the reference limit
ESR above reference limit
Positive Stool Test for Strongyloides stercoralis
Positive tests for viral hepatitis
Use of any systemic drug a month before the start of the study
There is a contraindication for betamethasone (diabetes, high blood pressure, drug allergy, active infection, recent surgery history, osteoporosis, stomach ulcer and psychosis, or depression)
Sensitivity to methotrexate
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Photographic Scoring for patients with Alopecia Areata. Timepoint: Before the start of the study and 3 , 6, 9 months after the start of treatment. Method of measurement: Photographic Scoring.;Visual Analogue Scale Score in patient with Alopecia Areata. Timepoint: Before the start of the study and 3 , 6, 9 months after the start of treatment. Method of measurement: Visual Analogue Scale.
- Secondary Outcome Measures
Name Time Method